Mepenzolate bromide

Mepenzolate bromide is a pharmacological agent classified as an anticholinergic. It is primarily used in the treatment of gastrointestinal disorders such as peptic ulcer disease and irritable bowel syndrome.

Pharmacology

Mepenzolate bromide works by blocking the action of acetylcholine, a neurotransmitter that stimulates the contraction of smooth muscles in the gastrointestinal tract. By inhibiting the action of acetylcholine, mepenzolate bromide reduces the motility and secretions of the gastrointestinal tract, thereby alleviating symptoms associated with disorders such as peptic ulcer disease and irritable bowel syndrome.

Clinical Use

Mepenzolate bromide is used in the management of gastrointestinal disorders that are characterized by hypermotility and excessive secretions. These include peptic ulcer disease, a condition characterized by the formation of ulcers in the lining of the stomach or the first part of the small intestine; and irritable bowel syndrome, a disorder that affects the large intestine and causes symptoms such as cramping, abdominal pain, bloating, gas, and diarrhea or constipation.

Side Effects

Like other anticholinergic drugs, mepenzolate bromide can cause a range of side effects. These may include dry mouth, blurred vision, constipation, difficulty urinating, and confusion. In rare cases, it can cause serious side effects such as an irregular heartbeat, difficulty breathing, and severe allergic reactions.

Contraindications

Mepenzolate bromide is contraindicated in patients with certain conditions such as glaucoma, myasthenia gravis, and obstructive uropathy. It should also be used with caution in elderly patients, who may be more susceptible to the side effects of the drug.

See Also

• Anticholinergic
• Peptic ulcer disease
• Irritable bowel syndrome
• Acetylcholine

‎